Brepocitinib for Hair Loss

(ALPINE Trial)

This trial tests the safety and effectiveness of an oral medication, brepocitinib, for treating hair loss caused by lichen planopilaris (LPP), a condition where the immune system attacks hair follicles. Participants will receive either brepocitinib or a placebo (a harmless pill with no active medicine) to evaluate its effectiveness. Individuals diagnosed with active LPP through a scalp biopsy and experiencing symptoms may be suitable for this study. As a Phase 2, Phase 3 trial, this research measures the treatment's effectiveness in an initial, smaller group and represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Previous studies found brepocitinib to be well tolerated by patients. Research has shown it to be safe for individuals with various types of hair loss, including alopecia. Participants in these studies did not experience any serious side effects. The treatment also led to noticeable hair regrowth and reduced inflammation. This suggests that brepocitinib could be a safe choice for those considering participation in a clinical trial for hair loss treatments.¹²³⁴⁵

Unlike the standard treatments for hair loss, which often include topical solutions like minoxidil or oral medications such as finasteride, Brepocitinib offers a novel approach. Brepocitinib works by targeting specific enzymes involved in the body's immune response, potentially reducing inflammation and promoting hair regrowth. Researchers are excited because this new mechanism of action may provide an alternative for those who haven't seen results with conventional therapies. Additionally, by acting on different biological pathways, Brepocitinib could offer a more personalized treatment option, addressing hair loss at its root cause for certain individuals.

This trial will evaluate brepocitinib's effectiveness for hair loss. Studies have shown that brepocitinib effectively treats various conditions by blocking certain proteins called TYK2 and JAK1. This action reduces inflammation, which is crucial in conditions like dermatomyositis and cutaneous sarcoidosis. In one study, patients with cutaneous sarcoidosis experienced significant improvement after taking brepocitinib. Although lichen planopilaris is a different condition, it also involves inflammation, so brepocitinib might help reduce symptoms by targeting the same pathways. The drug's mechanism and past successes in similar inflammatory conditions offer hope for its effectiveness in treating lichen planopilaris.⁶⁷⁸⁹¹⁰